Comparing Virtue, Consequentialist, and Deontological Ethics-Based Corporate Social Responsibility: Mitigating Microfinance Risk in Institutional Voids
- 期刊名称Journal of Business Ethics
- 作者Chakrabarty, Subrata; Erin Bass, A.
- 卷第126卷
- 期第3期
- 印刷ISSN0167-4544
- 电子ISSN1573-0697
- 文件大小557.27KB
- 发表时间2015-2
- DOI10.1007/s10551-013-1963-0
- 页码487-512
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?Faivre, Sandrine; de Gramont, Armand; Raymond, Eric · Targeted Oncology · 2016
Dissecting the mechanism of itch induced by sorafenib—Can sorafenib effect on mast cells?Mizukami, Yukari; Sugawara, Koji; Tsuruta, Daisuke · Journal of Dermatological Science · 2017
Combinatorial treatment of Rhizoma Paridis Saponins and sorafenib overcomes the intolerance of sorafenibYao, Jingwen; Man, Shuli; Dong, Honghong; Yang, Li; Ma, Long; Gao, Wenyuan · The Journal of Steroid Biochemistry and Molecular Biology · 2018
Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinomaZhao, Yang; Lai, JiaYing; Liang, RunBin; He, MinKe; Shi, Ming · Journal of Interventional Medicine · 2019
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and SorafenibJilaveanu, L.; Zito, C.; Lee, S. J.; Nathanson, K. L.; Camp, R. L.; Rimm, D. L.; Flaherty, K. T.; Kluger, H. M. · Clinical Cancer Research · 2009
Sorafenib Response in Hepatocellular Carcinoma: MicroRNAs as Tuning Forks miRNAs as regulators of sorafenib response in HCCKanthaje, Shruthi; Makol, Ankita; Chakraborti, Anuradha · Hepatology Research · 2017
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialProcopio, G; Verzoni, E; Bracarda, S; Ricci, S; Sacco, C; Ridolfi, L; Porta, C; Miceli, R; Zilembo, N; Bajetta, E · 2011
Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinomaF.C.S. Eng; A.M. Easson; E. Szentgyorgyi; J.J. Knox · 2009
Impaired PI3Wang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Endocrine · 2013
GabapentinWang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Reactions Weekly · 2013
AntineoplasticsWang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Reactions Weekly · 2013
ProgesteroneWang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Reactions Weekly · 2013
Dextromethorphan/quinidineWang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Reactions Weekly · 2013
CeftriaxoneWang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Reactions Weekly · 2013
Benzodiazepines/escitalopram/paroxetineWang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Reactions Weekly · 2013
Povidone iodineWang, Yan; Li, Baoxin; Zhang, Wei; Liu, Yan; Xue, Peng; Ma, Jianxia; Li, Yukun · Reactions Weekly · 2013
Biperiden/trihexyphenidylReactions Weekly · 1995
NitrendipineReactions Weekly · 2003
ScopolamineReactions Weekly · 2007
ScopolamineReactions Weekly · 2012
ScopolamineReactions Weekly · 2009
Centella asiaticaReactions Weekly · 2011
Daunorubicin/mitoxantroneReactions Weekly · 2007
AnthracyclinesReactions Weekly · 1991